Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.0%

20 terminated/withdrawn out of 133 trials

Success Rate

74.4%

-12.2% vs industry average

Late-Stage Pipeline

10%

13 trials in Phase 3/4

Results Transparency

36%

21 of 58 completed trials have results

Key Signals

14 recruiting21 with results14 terminated6 withdrawn

Enrollment Performance

Analytics

N/A

38(35.5%)

Phase 1

34(31.8%)

Phase 2

21(19.6%)

Phase 4

7(6.5%)

Phase 3

6(5.6%)

Early Phase 1

1(0.9%)

107Total

N/A(38)

Phase 1(34)

Phase 2(21)

Phase 4(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (133)

Showing 20 of 133 trials

NCT05389514Unknown

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Role: lead

NCT07408856Phase 1Recruiting

CAN1012 in Pre-Malignant DCIS and LCIS

Role: lead

NCT06175000Phase 2Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Role: lead

NCT05913388Phase 2Active Not Recruiting

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Role: lead

NCT06353997Phase 2Recruiting

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Role: lead

NCT04470024Phase 1Active Not Recruiting

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Role: lead

NCT05308901Phase 2Terminated

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Role: lead

NCT02306954Phase 2Active Not Recruiting

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Role: lead

NCT06719362Phase 1Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Role: lead

NCT03247712Phase 1Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Role: lead

NCT07614048Unknown

Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS

Role: lead

NCT07620496Phase 1Not Yet Recruiting

CAN1012 in Pre-malignant Oral Dysplasia

Role: lead

NCT03336606Phase 1Completed

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Role: lead

NCT05966038Recruiting

ALS/MND Natural History Study Data Repository

Role: collaborator

NCT06359587Not ApplicableRecruiting

Re-Purposing the Ordering of Routine Laboratory Tests in Hospitals in British Columbia

Role: collaborator

NCT06788145Not ApplicableNot Yet Recruiting

Enhancing Social Connections Among Rural Community Members With Disordered Eating

Role: collaborator

NCT03289364Not ApplicableCompleted

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

Role: lead

NCT05349890Phase 1Active Not Recruiting

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Role: lead

NCT02734290Phase 1Active Not Recruiting

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Role: lead

NCT02812524Phase 1Active Not Recruiting

Ipilimumab for Head and Neck Cancer Patients

Role: lead